Abstract
Carcinogenesis proceeds through a very long preclinical period. Our collective hope is that multiple opportunities exist for chemoprevention to arrest or reverse progression towards malignancy. In the hope of faster progress with fewer subjects and lower total cost, much effort is being expended on the search for reliable biomarkers to predict the likelihood of developing cancer and/or to signal the effectiveness of chemopreventive therapy. Considerable attention is paid to identifying those markers that can act as surrogate markers for cancer development, since favorable modulation of the surrogate end point biomarker (SEBM) may demonstrate effectiveness of a putative preventive treatment. However, the complexity of the biology challenges our ability to measure the effectiveness of attempts to arrest or reverse carcinogenesis, other than through costly and time-consuming prospective trials with disease state as the endpoint. Despite much work, to date no prehistologic biological or molecular intermediate marker has been validated for sporadic cancers. Several factors accounting for the difficulties encountered in SEBM development are reviewed. Discussion is focused on the common thread of the complexity of the underlying biological changes in carcinogenesis limiting the effectiveness of any single biomarker. Additionally, the incidence of sporadic cancers is also low, further limiting the positive predictive value of any putative prognostic marker. Recent successes in development of chemopreventive agents show the concept is valid and worth pursuing, but the current strategies to develop biochemical and genetic markers to identify surrogate biomarkers is flawed, and need to be reassessed in light of the difficulties faced over the last 20 years.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
[No authors listed] (1975) Clofibrate and niacin in coronary heart disease. JAMA 231:360–381
[No authors listed] (1979) Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 242:2562–2567
[No authors listed] (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 324: 509–516
[No authors listed] (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265:3255–3264
[No authors listed] (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 327:227–233
[No authors listed] (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029–1035
[No authors listed] (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389
[No authors listed] (1997) Food and Drug Modernization Act. Title 21Code of Federal Regulations Part 314 Subpart H Sections 314.500-314.520
[No authors listed] (2000) Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses 16:1123–1133
[No authors listed] (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
[No authors listed] (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
Armstrong WB, Taylor TH, Meyskens FL Jr (2003) Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:589–592
Califano J, van der Riet P, Westra W, et al (1996) Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488–2492
Coplen SE, Antman EM, Berlin JA, et al (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82: 1106–1116
Echt DS, Liebson PR, Mitchell LB, et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781–788
Edwards AL (1967) Statistical methods. Holt Rinehart and Winston, New York
Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613
Gilbert PB, DeGruttola V, Hammer SM, et al (2001) Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA 285:777–784
Gordon DJ (1994) Cholesterol lowering and total mortality. In: Rifkind BM (ed) Contemporary issues in cholesterol lowering: clinical and population aspects. Marcel Dekker, New York
Hahn WC, Counter CM, Lundberg AS, et al (1999) Creation of human tumour cells with defined genetic elements [see comments]. Nature 400: 464–468
Held PH, Yusuf S, Furberg CD (1989) Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 299: 1187–1192
Herrington DM, Howard TD (2003) From presumed benefit to potential harm—hormone therapy and heart disease. N Engl J Med 349: 519–521
Hine LK, Laird N, Hewitt P, et al (1989) Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 149:2694–2698
Hodis HN, Mack WJ, Azen SP, et al (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349:535–545
Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90:85–91
Kelloff GJ, Malone WF, Boone CW, et al (1990) Progress in applied chemoprevention research. Semin Oncol 17:438–455
Kelloff GJ, O’shaughnessy JA, Gordon GB, et al (2003) Counterpoint: because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:593–596
Kelloff GJ, Sigman CC, Johnson KM, et al (2000) Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9:127–137
Lederman HM, Williams PL, Wu JW, et al (2003) Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 188:1794–1803
Lippman SM, Hong WK (2002) Cancer prevention by delay. Commentary re: JA O’shaughnessy et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346, 2002. Clin Cancer Res 8:305-346
Manson JE, Hsia J, Johnson KC, et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534
Matsuhashi N, Nakajima A, Shinohara K, et al (1998) Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am J Gastroenterol 93:2261–2266
Omenn GS, Goodman GE, Thornquist MD, et al (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial [see comments]. J Natl Cancer Inst 88: 1550–1559
O’shaughnessy JA, Kelloff GJ, Gordon GB, et al (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346
Packer M, Carver JR, Rodeheffer RJ, et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468–1475
Packer M, Rouleau J, Swedberg K, et al (1993) Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study (abstract). Circulation 88 Suppl 1):I
Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431–440
Riggs BL, Hodgson SF, O’Fallon WM, et al (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–829
Sande MA, Carpenter CC, Cobbs CG, et al (1993) Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA 270:2583–2589
Schatzkin AGail M (2002) The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2:19–27
Siscovick DS, Raghunathan TE, Psaty BM, et al (1994) Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330:1852–1857
Takala J, Ruokonen E, Webster NR, et al (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785–792
Temple R (1999) Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282:790–795
Thompson IM, Goodman PJ, Tangen CM, et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224
Tonelli F, Valanzano R, Messerini L, et al (2000) Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 74:15–20
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Armstrong, W.B., Taylor, T.H., Meyskens, F.L. (2005). Can a Marker Be a Surrogate for Development of Cancer, and Would We Know It if It Exists?. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics III. Recent Results in Cancer Research, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26980-0_8
Download citation
DOI: https://doi.org/10.1007/3-540-26980-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22228-6
Online ISBN: 978-3-540-26980-9
eBook Packages: MedicineMedicine (R0)